Latest news
Cristal Therapeutics appoints Dr Werner Cautreels as a new Director and Board Chairman and Andre Verwei as Chief Financial Officer
Maastricht, The Netherlands, 1st August 2019 – Cristal Therapeutics, a Phase 2 clinical stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, announces that Dr Werner Cautreels is...
Confo Therapeutics and DyNAbind announce drug discovery collaboration to identify novel GPCR-modulating compounds
Ghent, Belgium, and Dresden, Germany - 3 July 2019 – Confo Therapeutics, an emerging drug discovery company, and DyNAbind GmbH today announce a drug discovery collaboration on an undisclosed G-protein coupled receptor (GPCR). The collaboration will combine...
Confo Therapeutics receives €1.7 million grant from VLAIO to progress novel GPCR-modulating compounds for an orphan indication
Ghent, Belgium, 20 June 2019 – Confo Therapeutics, an emerging drug discovery company, today announces that it has been awarded a €1.7 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant will run over two years and will support one of the...
ADC Therapeutics Expands to Third Program Using Synaffix’s ADC Platform under Existing Agreement
AMSTERDAM, NETHERLANDS – May 28, 2019 – Synaffix B.V., a Dutch biotechnology company focused on the advancement of its clinical-stage antibody-drug conjugate (ADC) technology for the development of best-in-class ADCs, announces that ADC Therapeutics has triggered a...
Next events
Nordic Life Science days Malomo Copenhagen – September 10 / 12
Daniela will attend the Nordic Life Science days in Malomo Copenhagen. https://www.nlsdays.com/
BIO-Europe Hamburg – November 11/ 13
BGV will attend the BIO-Europe in Hamburg. https://ebdgroup.knect365.com/bioeurope/
ASH: American Society of Hematology Orlando – December 7/ 10
Edward will attend the ASH conference in Orlando. https://www.hematology.org/Annual-Meeting/
Latest investments
